Investigating factors that contribute to resistance in breast cancer treatment
Official title: Targeting secreted factors in endocrine resistant breast cancer therapy
Funded at Albany College of Pharmacy · NIH-10654343 · Data updated 2026-11-12
This study is looking at how some breast cancer cells talk to the surrounding tissue, especially when they stop responding to regular hormone treatments, to find new ways to help patients get better.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albany College of Pharmacy NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $480,000 |
| NIH project number | 1R15CA271221-01A1 |
| Project ID | NIH-10654343 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are postmenopausal women with early-stage breast cancer who have developed resistance to endocrine therapies.
✕Less likely to help
Patients with non-endocrine resistant breast cancer or those not undergoing endocrine therapy may not benefit from this research.
What this research studies
This research focuses on understanding how certain breast cancer cells communicate with surrounding tissue, particularly in cases where the cancer has become resistant to standard hormone therapies. By studying specific proteins and factors involved in this communication, the researchers aim to uncover mechanisms that allow cancer cells to thrive despite treatment. The project involves creating and analyzing different breast cancer cell lines to identify key factors that could be targeted for new therapies. Ultimately, the goal is to develop strategies that can block harmful interactions between cancer cells and their environment, potentially leading to more effective treatments for patients.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve outcomes for patients with endocrine-resistant breast cancer.
How similar studies have gone: Previous research has shown promise in targeting communication pathways in cancer, suggesting that this approach could yield valuable insights and potential breakthroughs.
Where this research is happening
-
Albany College of Pharmacy
Albany, United States Active
Researchers
- Principal investigator: Jin, Kideok — Albany College of Pharmacy
- Study coordinator: Jin, Kideok
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.